Mon, 2010-11-08 13:00
This is important timing, as GlaxoSmithKline is apparently considering pulling Bexxar from the market. The problem with both Bexxar and Zevalin is that so few oncologists are aware of these treatments, and often those that are don't have a stake in referring patients to treatment, so they don't even mention it. There's an online petition to keep Bexxar on the market, if interested check it out HERE.
© 2013 SupportGroups.com